arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Kalaris Therapeutics, Inc.

KLRS
$3.15 ▼ -0.12 (-3.82%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
31 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Kalaris Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $75.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -17.0%
FCF / Share $-0.46
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-10.86M
↓ -6.5%
FCF / Share Free cash flow per share
$-0.46
↑ +4.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Financial Health
20
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters